Interindividual and Intra-Individual Variabilities of Darunavir and Ritonavir Plasma Trough Concentrations in Multidrug Experienced HIV Patients Receiving Salvage Regimens

摘要: BACKGROUND: There is no consensus on darunavir (DRV) target levels in plasma for clinical use, and information about variability concentrations limited. AIM: : To investigate the DRV trough setting, evaluating interindividual intraindividual variabilities of drug among HIV-infected patients receiving ritonavir (RTV)-boosted (DRV/r) within salvage regimens, evaluate potential correlation between virological response. METHODS: Sixty-two taking DRV/r (600/100 mg twice a day) were evaluated immunovirological parameters after 6 months from start regimen. A subgroup (n = 21) was also (expressed as coefficient variation) 2 samples taken at different time points. Drug assayed by high-performance liquid chromatography with ultraviolet detection, values expressed medians interquartile range (IQR). Genotypic sensitivity score genotypic inhibitory quotient calculated. RESULTS: used median 3 other antiretroviral drugs (raltegravir use 88.7%). Median 3.22 mcg/mL (IQR, 2.04-5.69) 0.44 0.21-0.70) RTV. Both showed high (61% 99.3%, respectively). Only (4.8%) had undetectable levels. significant positive age (r 0.298, P 0.019), but HIV-RNA (P 0.614) found. Intraindividual coefficients variation 58.4% 47.1% Patients trend lower compared detectable (55.9% versus 83.8%, 0.156). No major interaction effects CONCLUSIONS: In context therapy, both RTV variabilities. Lower could be beneficial maintaining viral suppression.